{
  "nctrialId": "HC-1859",
  "title": "A  Open-Label, Active-Controlled  Study of MEL-802 (checkpoint inhibitor) in Patients With Cystic Fibrosis",
  "officialTitle": "A  Open-Label, Active-Controlled  Study of MEL-802 (checkpoint inhibitor) in Patients With Cystic Fibrosis",
  "sponsor": "Sunnybrook Research Institute",
  "indication": "Cystic Fibrosis",
  "phase": "Phase 1/Phase 2",
  "fileName": "HC-1859.json",
  "fileSize": 161108,
  "date": "2024-05-13",
  "completionDate": "2027-04-07",
  "drugName": "MEL-802 (checkpoint inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Recruiting",
  "description": "This is a  open-label, active-controlled  study designed to evaluate the efficacy and safety of MEL-802 (checkpoint inhibitor) in patients with Cystic Fibrosis. The study will enroll approximately 419 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 26-74 years\n- Confirmed diagnosis of Cystic Fibrosis\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment",
  "csr_id": "HC-1859"
}